The numbers of patients excluded due to lack of follow-up after the index date were 348 of 15 182 (2.3%) prescribed tirzepatide and 4141 of 129 615 (3.2%) prescribed a GLP-1 RA. This evidence concerns the gene GLP1R and rheumatoid arthritis.